Intensity Therapeutics Inc (Nasdaq:INTS), a late-stage clinical biotechnology company, announced on Thursday that it has been named a winner of the 2026 GHP Magazine Healthcare & Pharmaceutical Awards as the Cancer Treatment Technology Innovator of the Year 2026 - USA award recipient.

GHP Magazine's judging panel recognised Intensity Therapeutics as a leader in the research and development of intratumoural injection drug delivery technology. This followed a rigorous, merit-based evaluation of Intensity's innovation, business performance, and overall impact on patient outcomes, the company said.

Welcoming the award, Intensity's co-founder and CEO Lewis H. Bender said: "By offering a novel methodology for inducing cancer cell death reducing tumour burden without significant off target toxicities -- the drug stays in the tumour, and inducing a systemic anticancer immune response, INT230-6 has the potential to turn aggressive, immunotherapy-resistant malignancies into manageable, chronic conditions."